Navigation Links
BioMS Medical to present at UBS Global Life Sciences Conference
Date:9/19/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the UBS Global Life Sciences Conference in New York.

WHEN: Monday September 22nd at 10:00am (Eastern Time)

WHERE: Grand Hyatt New York, New York

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
2. BioMS Medical announces its intention to renew a normal course issuer bid
3. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
4. BioMS Medical Announces Second Quarter 2008 Results
5. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
6. BioMS Medical to present at BMO Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at Jefferies Healthcare Conference
9. BioMS Medical to present at 2008 BIO International Convention
10. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
11. BioMS Medical announces first quarter 2008 results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Boston, Massachusetts (PRWEB) , ... May 23, 2017 , ... ... is making a splash at this year’s Bio-IT World Conference and Expo ... Anzo Smart Data Lake® 4.0 solution. The Anzo Smart Data Lake is also ...
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer diagnostics and ... booth B2 at the Association for Pathology Informatics Annual Summit at ... to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research ...
(Date:5/19/2017)... ... 2017 , ... The University City Science Center is seeking ... commercialization, and who are affiliated with the 21 partner academic and research institutions ... in its tenth round, is the first multi-institutional proof-of-concept program for the life ...
(Date:5/18/2017)... VIRGINIA (PRWEB) , ... May 17, 2017 , ... NDA ... business executive and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development ... addition to his position at Eurofins and Cardinal Health, he was former Chief Operating ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):